A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while ...

Biopharma venture capital fundraising declined from $8.1 billion in the first quarter of 2024 to $6.5 billion in the first ...

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

Twenty attorneys general allege that the recent workforce reduction at the Department of Health and Human Services is ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...